SBIR-STTR Award

Development of Novel Fast Gpu Monte Carlo and Active Photonics Simulation Software for Predicting Pdt Efficacy
Award last edited on: 1/24/18

Sponsored Program
SBIR
Awarding Agency
NIH : NCI
Total Award Amount
$1,692,668
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Mary Potasek

Company Information

Simphotek Inc

211 Warren Street
Newark, NJ 07103
   (609) 921-1338
   beesonk@aol.com
   www.simphotek.com
Location: Single
Congr. District: 10
County: Essex

Phase I

Contract Number: 1R43CA183236-01A1
Start Date: 9/17/14    Completed: 5/31/15
Phase I year
2014
Phase I Amount
$225,000
Photodynamic therapy (PDT) is used for treating a variety of medical conditions including cancer. Even after many years of PDT research and the large-scale use of PDT treatments by physicians, there are many aspects of PDT, such as quantitative predictions for diffusive light propagation and the kinetics of the light-material interactions, that are not well understood. This can lead to a large variation in treatment results In particular, the dosimetry for treatments is challenging and it is difficult to determine the lasr light energies and the photosensitizer (PS) concentrations that are optimal. In this Phase I SBIR, Simphotek (prime institution), Tech-X (subaward institution) and University of Pennsylvania School of Medicine, i.e. UPenn (subaward institution) will investigate the feasibilityof experimentally (UPenn) and computationally (Simphotek/Tech-X) guiding novel and easy-to-use mathematical and numerical methods for PDT. The software product(s) that result(s from the Phase I and Phase II SBIRs will be commercialized for PDT researchers, companies and medical personnel. This exploratory, yet crucial, project combines the knowledge of experts in several disciplines, including optics, mathematics and computer science (Simphotek), numerical algorithms for fast graphical processing units (GPUs) and Monte Carlo calculations (Tech-X) and medical physicists and translational biologists in PDT (UPenn). The commercialized software that results from the Phase I and Phase II SBIRs, will direct the resulting products to PS and PDT researchers and to PDT users worldwide.

Thesaurus Terms:
Absorption;Algorithms;Attenuation;Bacterial Infections;Base;Biological;Blood Product;Cardiovascular Diseases;Clinical;Clinical Application;Code;Complex;Computer Framework;Computer Science;Computer Software;Computing Methodologies;Design;Development;Discipline;Dosimetry;Electromagnetic Energy;Electromagnetic Fields;Electromagnetics;Equation;Experience;Eye Diseases;Faculty;Geometry;Goals;Health Personnel;High Performance Computing;Improved;Institution;Investigation;Kinetics;Knowledge;Language;Laptop;Lasers;Lead;Light;Malignant Neoplasms;Mathematical Algorithm;Mathematical Methods;Mathematics;Medical;Medical Schools;Member;Methods;Model Development;Modeling;Monte Carlo Method;Mouth Diseases;Novel;Optics;Parallel Computer;Particle;Pennsylvania;Phase;Photochemotherapy;Photonics;Photosensitizing Agents;Physicians;Plasma;Pre-Clinical;Process;Programs;Property;Public Health Relevance;Research Infrastructure;Research Personnel;Response;Series;Simulation;Simulation Software;Skin Disorder;Small Business Innovation Research Grant;Software Development;Solutions;Therapeutic;Therapeutic Studies;Tissues;Treatment Planning;Tumor Biology;Universities;User Friendly Software;User-Friendly;Variant;Weight;Work;

Phase II

Contract Number: 2R44CA183236-02A1
Start Date: 9/17/14    Completed: 5/31/18
Phase II year
2016
(last award dollars: 2017)
Phase II Amount
$1,467,668

Photodynamic therapy (PDT) provides for standalone or intraoperative cancer treatment. PDT provides a means to treat superficial and/or residual disease, while minimizing damage to underlying tissues, and does not exhibit cumulative cell toxicities, distinguishing it from radiation therapy. As compared to radiotherapy, treatment planning in PDT is often approached in a one-size-fits-all fashion. However, patient- and tumor-specific factors such as tissue optical properties and photosensitizer (PS) levels are critical to the delivery of effective light doses. The development of treatment dosimetry tools tha take into account these factors will fill an unmet clinical need and provide for individualized patient treatment. An effective PDT treatment dosimetry system stands to improve therapeutic outcomes, reduce the need for repeat PDT or additional cell-killing therapy, and could therefore reduce overall costs in the per patient delivery of cancer-related therapy and care. The major objective of this SBIR Phase II proposal is to develop and verify prototype software and hardware tools that combine simulations of PS photophysics with light propagation using fast Monte-Carlo (MC) techniques. The research of this Phase II SBIR will result in unique prototype dosimetry tools that will be further developed and commercialized in Phase III for use by PDT physicians and researchers to improve patient outcomes. This Phase II SBIR has three major aims. Aim 1 is to develop prototype software for PDT dosimetry combining light transport using fast Monte-Carlo (MC) techniques and patient PS variability. The software should be fast enough for future clinical use in Phase III of this project. At the foundation of this system will e Simphotek's novel Active Photonics Building Blocks (APBB) algorithm with its simple graphical user interface for active photophysics. The APBB breaks the computing problem for photophysics into a series of computational building blocks that the software automatically combines to generate the full numerical simulation. To include light scattering in the analysis, Simphotek has partnered with Tech-X Corporation (Tech-X; subaward), a leader in the field of high-performance computing. Tech-X has developed MC-based scattering infrastructure and has adapted the code in Phase I to model light diffusion and absorption processes in biological tissue. The Aim 2 objective is for Tech-X and Simphotek to develop a prototype PDT dosimetry tool combining both the software developed in Aim 1 and specialized hardware for high-speed simulations. Aim 3 is to verify the software/hardware simulations by comparing the simulation results to phantom measurements done at the University of Pennsylvania School of Medicine (Penn; subaward) by experts in PDT.

Public Health Relevance Statement:


Public Health Relevance:
A critical barrier to continued progress in photodynamic therapy (PDT) cancer treatments is the general lack of effective treatment dosimetry tools that can provide for individualized patient treatments. Our multidisciplinary team proposes to fill this unmet need by greatly improving the computational methods for PDT and subsequently developing unique prototype treatment dosimetry tools that can be easily utilized by PDT physicians and researchers. An effective PDT treatment dosimetry system stands to improve patient outcomes, reduce the need for repeat PDT or additional cell-killing therapy, and could therefore reduce overall costs in the per patient delivery of cancer-related therapy and care.

Project Terms:
absorption; Acceleration; Accounting; Aftercare; Air; Algorithms; base; Biological; cancer therapy; Caring; cell killing; Cells; Clinical; clinically relevant; Code; Complex; Computer Architectures; Computer software; Computers; Computing Methodologies; cost; cytotoxic; Cytotoxic Chemotherapy; Development; Diffusion; Disease; Dose; Dose-Rate; dosimetry; Drug Interactions; effective therapy; Electromagnetic Energy; Equation; Exhibits; Foundations; Future; Goals; graphical user interface; high end computer; High Performance Computing; Hour; improved; individualized medicine; innovation; Kinetics; Legal patent; Light; light scattering; Liquid substance; Malignant Neoplasms; Measurement; Measures; medical schools; meetings; Modeling; multidisciplinary; Nature; neglect; novel; Optics; Patient-Focused Outcomes; Patients; Pennsylvania; Phase; Photobleaching; photonics; Photons; Physicians; Positioning Attribute; Process; Property; prototype; public health relevance; PUVA Photochemotherapy; Radiation therapy; Reaction; Reporting; Research; research clinical testing; Research Infrastructure; Research Personnel; Residual Tumors; Series; simulation; simulation software; Singlet Oxygen; Small Business Innovation Research Grant; software development; Software Tools; Source; Speed; Surface; System; Techniques; therapy development; therapy outcome; Tissues; tool; Toxic effect; Treatment Efficacy; treatment planning; Treatment-Related Cancer; tumor; Universities; user friendly software; Writin